08:08 AM EDT, 04/03/2024 (MT Newswires) -- Eli Lilly's ( LLY ) diabetes drug Mounjaro's four higher doses will be available in limited amounts through April due to increased demand, the US Food and Drug Administration's website showed.

The health regulator noted that the 7.5, 10, 12.5, and 15-milligram doses will have limited availability, while lower doses are shown available on the FDA website.

The FDA earlier said three higher doses of Mounjaro, chemically known as tirzepatide, would remain in tight supply through early March.

Approved in 2022 to manage blood sugar levels in type-2 diabetes patients, Mounjaro secured FDA approval for weight loss in the US last year.

Eli Lilly ( LLY ) shares were 0.4% higher in recent premarket trading.

Price: 765.56, Change: +1.6, Percent Change: +0.21